This is default featured slide 1 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 2 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 3 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 4 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 5 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

India pharma sector to miss 2030 sales target amid tariff and shipping woes, trade body says

India's pharmaceutical industry is expected to reach$80-90 billion by 2030, well below its earlier$130 billion target, as U.S. tariff uncertainty and Middle East shipping disruptions hurt exports, Pharmaceuticals Export Promotion Council of India Chairman Namit Joshi told Reuters.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/867Jmlf
via IFTTT

Private equity firm Creador in talks to buy into generic drug co Leeford Health

Private equity firm Creador is in advanced talks to acquire a stake. The firm expects to invest ₹800 crore in Leeford Healthcare. This acquisition would value the generic drugmaker at ₹8,000-₹8,500 crore. Leeford Healthcare is a diversified pharmaceutical and wellness company. This deal marks the company's first ownership dilution to an external investor.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Kf5xhTv
via IFTTT

Two-wheeled road ambulance to run from October 1, 2027

The Centre has proposed introducing a regulatory framework for two-wheeled road ambulances, which will become operational from October 1, 2027, to improve emergency medical access in rural, remote and hilly areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kKeP0ZV
via IFTTT

Losing weight fast on GLP-1 drugs? Your hair could be the next thing to go

Dermatologists report increased hair loss among GLP-1 drug users experiencing rapid weight reduction. This side effect, often telogen effluvium, stems from nutritional deficiencies and metabolic stress. Many patients start these medications without proper medical supervision, influenced by social media trends. Studies show a high prevalence of hair shedding, particularly among women and significant weight losers. Doctors advise medical supervision and balanced nutrition to manage this temporary condition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iSpeEKr
via IFTTT

India's Second Leapfrog: From sick-care to AI-native health infrastructure

Just as India bypassed copper landlines to become a global mobile data leader, it can now bypass the West's CPT-coded sick-care bureaucracy and build AI-powered, personalised healthspan infrastructure for the world.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VWaiTPn
via IFTTT

GLP-1 demand stirs up hunger for obesity care talent

Demand for nutrition professionals is rapidly increasing across India. Hospitals and digital health platforms are hiring more dietitians and educators. This trend supports patients using new GLP-1 obesity medications. Specialized obesity care teams are expanding to meet growing patient needs. Long-term monitoring and lifestyle support are crucial for sustained health outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7SEy0he
via IFTTT

Jackson Labs' Baddi drug manufacturing licence restored after suspension

The unit's licence was cancelled in June after several women in Kota, Rajasthan, died allegedly due to spurious oxytocin injections supplied by the company's Punjab unit.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/agUXoKF
via IFTTT